These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39214389)

  • 1. Improvement in high-density lipoprotein cholesterol in people with HIV who switched from a tenofovir alafenamide-containing regimen to cabotegravir plus rilpivirine.
    Muccini C; Diotallevi S; Lolatto R; Piromalli G; Spagnuolo V; Castagna A
    Int J Antimicrob Agents; 2024 Oct; 64(4):107312. PubMed ID: 39214389
    [No Abstract]   [Full Text] [Related]  

  • 2. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
    PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
    Mu Y; Pham M; Podany AT; Cory TJ
    Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
    [No Abstract]   [Full Text] [Related]  

  • 6. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
    Mills AM; Rizzardini G; Ramgopal MN; Osiyemi OO; Bogner JR; Hagins DP; Paredes R; Reynes J; Rockstroh JK; Carr A; Su FH; Klopfer SO; Eves K; Plank RM; Correll T; Fox MC
    Lancet HIV; 2024 Jun; 11(6):e357-e368. PubMed ID: 38734016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
    Ramgopal MN; Castagna A; Cazanave C; Diaz-Brito V; Dretler R; Oka S; Osiyemi O; Walmsley S; Sims J; Di Perri G; Sutton K; Sutherland-Phillips D; Berni A; Latham CL; Zhang F; D'Amico R; Pascual Bernáldez M; Van Solingen-Ristea R; Van Eygen V; Patel P; Chounta V; Spreen WR; Garges HP; Smith K; van Wyk J
    Lancet HIV; 2023 Sep; 10(9):e566-e577. PubMed ID: 37567205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis.
    Yoo JJ; Jung EA; Kim SG; Kim YS; Kim MJ
    J Int AIDS Soc; 2024 Sep; 27(9):e26358. PubMed ID: 39301685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
    Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
    AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV.
    Mazzitelli M; Agostini E; Vania E; Presa N; Sasset L; Leoni D; Gardin S; Scaglione V; Cattelan A
    HIV Res Clin Pract; 2024 Dec; 25(1):2351258. PubMed ID: 38726811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
    Wohl DA; Spinner CD; Flamm J; Hare CB; Doblecki-Lewis S; Ruane PJ; Molina JM; Mills A; Brinson C; Ramgopal M; Clarke A; Crofoot G; Martorell C; Carter C; Cox S; Hojilla JC; Shao Y; Das M; Kintu A; Baeten JM; Grant RM; Mounzer K; Mayer K
    Lancet HIV; 2024 Aug; 11(8):e508-e521. PubMed ID: 39008999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
    Taramasso L; Berruti M; Briano F; Di Biagio A
    AIDS; 2020 May; 34(6):877-881. PubMed ID: 32271252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
    Orkin C; Ajana F; Kityo C; Koenig E; Natukunda E; Gandhi-Patel B; Wang H; Liu Y; Wei X; White K; Makadzange T; Pikora C; McNicholl I; Collins SE; Brainard D; Chuck SK
    J Acquir Immune Defic Syndr; 2021 Dec; 88(4):393-398. PubMed ID: 34506342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine.
    Muccini C; Gianotti N; Lolatto R; Nozza S; Diotallevi S; Castagna A
    AIDS; 2024 Nov; 38(13):1890-1892. PubMed ID: 39325006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine.
    Vélez-Díaz-Pallarés M; Gramage-Caro T; Rodríguez-Sagrado MÁ; Montero-Llorente B; Bermejo-Vicedo T
    Biomedica; 2020 May; 40(Supl. 1):132-138. PubMed ID: 32463615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
    d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
    J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
    Mills A; Arribas JR; Andrade-Villanueva J; DiPerri G; Van Lunzen J; Koenig E; Elion R; Cavassini M; Madruga JV; Brunetta J; Shamblaw D; DeJesus E; Orkin C; Wohl DA; Brar I; Stephens JL; Girard PM; Huhn G; Plummer A; Liu YP; Cheng AK; McCallister S;
    Lancet Infect Dis; 2016 Jan; 16(1):43-52. PubMed ID: 26538525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
    Orkin C; Antinori A; Rockstroh JK; Moreno-Guillén S; Martorell CT; Molina JM; Lazzarin A; Maggiolo F; Yazdanpanah Y; Andreatta K; Huang H; Hindman JT; Martin H; Pozniak A
    AIDS; 2024 Jun; 38(7):983-991. PubMed ID: 38349226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine.
    Mazzitelli M; Avolio A; Carandina R; Parisi S; Wensing A; Cattelan A
    J Antimicrob Chemother; 2024 Aug; 79(8):2074-2076. PubMed ID: 38905150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.